Zoetis to acquire Nexvet Veterinary Biologic Therapeutics Co.April 13, 2017Zoetis Inc. announced it will purchase Nexvet Biopharma veterinary biologic therapeutics company for US $6.72 per share, or a valuation of approximately US $85 million. Pending approval, the purchase is expected to be completed during the second half of 2017.
SPONSORED CONTENTYear-Round Tick Control is ImportantEmpower dog owners to protect their dogs with protection approved by the FDA for the prevention of Lyme infections in dogs as a direct result of killing black-legged ticks. + Learn More
